AI in Breast Imaging Accelerates Toward Regulated Automation

SimBioSys reported FDA 510(k) clearance on October 15, 2026, for TumorSight Risk, retrospectively validated across 2,129 patients; prospective utility, calibration, treatment impact, reimbursement, equity, and outcomes remain unresolved. MASAI found noninferiority—not superiority or mortality benefit—and Lunit announced Saudi deployment without performance or outcome data. DeepLook’s reported deployments and a separate early decision-support development report add adoption and development signals, but workflow fit, representative data, and clinical impact remain key tests.